These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 31260082)

  • 1. Rapid response of pityriasis rubra pilaris with psoriasis overlap to secukinumab.
    Cole D; Mohammad T; Lim H
    Br J Dermatol; 2019 Dec; 181(6):1331-1332. PubMed ID: 31260082
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of Pityriasis Rubra Pilaris With Guselkumab.
    Pilz AC; Seiringer P; Biedermann T; Eyerich K
    JAMA Dermatol; 2019 Dec; 155(12):1424-1426. PubMed ID: 31577328
    [No Abstract]   [Full Text] [Related]  

  • 3. Evaluation of Ixekizumab Treatment for Patients With Pityriasis Rubra Pilaris: A Single-Arm Trial.
    Haynes D; Strunck JL; Topham CA; Ortega-Loayza AG; Kent G; Cassidy PB; Hu R; Choate K; Wang Z; Liu Y; Greiling TM
    JAMA Dermatol; 2020 Jun; 156(6):668-675. PubMed ID: 32293641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A case of treatment-resistant pityriasis rubra pilaris responsive to secukinumab.
    Simpson K; Dolianitis C
    Australas J Dermatol; 2021 Aug; 62(3):441-442. PubMed ID: 34028789
    [No Abstract]   [Full Text] [Related]  

  • 5. Secukinumab emerges as a rapidly effective therapy for pityriasis rubra pilaris.
    Bonomo L; Levitt JO
    Cutis; 2018 May; 101(5):367-369. PubMed ID: 29894526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adalimumab for the treatment of pityriasis rubra pilaris: a case report.
    Wassef C; Lombardi A; Rao BK
    Cutis; 2012 Nov; 90(5):244-7. PubMed ID: 23270195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case of juvenile pityriasis rubra pilaris type III successfully treated with etanercept.
    Lora V; De Felice C; Cota C; Graceffa D; Morrone A; Bonifati C
    Dermatol Ther; 2018 Jan; 31(1):. PubMed ID: 29193567
    [No Abstract]   [Full Text] [Related]  

  • 8. Secukinumab for the treatment of adult-onset pityriasis rubra pilaris: a single-arm clinical trial with transcriptomic analysis.
    Boudreaux BW; Pincelli TP; Bhullar PK; Patel MH; Brumfiel CM; Li X; Heckman MG; Pittelkow MR; Mangold AR; Sluzevich JC
    Br J Dermatol; 2022 Nov; 187(5):650-658. PubMed ID: 35701384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exacerbation of pityriasis rubra pilaris under efalizumab therapy.
    Klein A; Szeimies RM; Landthaler M; Karrer S
    Dermatology; 2007; 215(1):72-5. PubMed ID: 17587845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pityriasis rubra pilaris : Successful treatment with ixekizumab].
    Kohn D; Wetzig T
    Hautarzt; 2020 Aug; 71(8):624-626. PubMed ID: 32185430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid response of erythrodermic pityriasis rubra pilaris to tildrakizumab.
    Villa-Gonzalez JM; Gonzalez-Hermosa MR; Atxutegi-Ayesta X; Ratón Nieto JA; Gardeazabal García J; Lasa Elgezua O
    Clin Exp Dermatol; 2024 Jan; 49(2):177-180. PubMed ID: 37847660
    [No Abstract]   [Full Text] [Related]  

  • 12. Risankizumab for pityriasis rubra pilaris.
    Brocco E; Laffitte E
    Clin Exp Dermatol; 2021 Oct; 46(7):1322-1324. PubMed ID: 33914925
    [No Abstract]   [Full Text] [Related]  

  • 13. Pityriasis Rubra Pilaris Response to IL-17A Inhibition Is Associated with IL-17C and CCL20 Protein Levels.
    Strunck JL; Cutler B; Rajpal B; Kent G; Haynes D; Topham CA; Ortega-Loayza AG; Yang D; Wang Z; Liu Y; Cassidy P; Greiling TM
    J Invest Dermatol; 2022 Jan; 142(1):235-239.e1. PubMed ID: 34246621
    [No Abstract]   [Full Text] [Related]  

  • 14. Pityriasis rubra pilaris with polyarthritis treated with adalimumab.
    Chiu HY; Tsai TF
    J Am Acad Dermatol; 2013 Jan; 68(1):187-8. PubMed ID: 23244382
    [No Abstract]   [Full Text] [Related]  

  • 15. Secukinumab is an effective and safe treatment for refractory pityriasis rubra pilaris.
    Papini M; Russo A; Natalini Y; Troiani L; Cassiani L
    Ital J Dermatol Venerol; 2021 Aug; 156(4):501-502. PubMed ID: 33179881
    [No Abstract]   [Full Text] [Related]  

  • 16. Secukinumab monotherapy successfully treated severe refractory type V (atypical juvenile) pityriasis rubra pilaris: A case report and literature review.
    Liang JY; Ye RX; Tian X; Zhang SQ; Zhang XB
    Dermatol Ther; 2020 Nov; 33(6):e14097. PubMed ID: 32725719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment of severe pityriasis rubra pilaris with secukinumab in a 3-year-old boy.
    Xu YH; Dong DD; Lin YF; Wang Q; Huang LM; Shi JQ
    Clin Exp Dermatol; 2022 Nov; 47(11):2043-2045. PubMed ID: 35906074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methotrexate treatment in a case of juvenile pityriasis rubra pilaris.
    Boyd AH; Polcari IC
    Pediatr Dermatol; 2018 Jan; 35(1):e62-e63. PubMed ID: 29044698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical improvement of pityriasis rubra pilaris with efalizumab in a pediatric patient.
    Gómez M; Ruelas ME; Welsh O; Arcaute HD; Ocampo-Candiani J
    J Drugs Dermatol; 2007 Mar; 6(3):337-9. PubMed ID: 17373198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case of pityriasis rubra pilaris with focal acantholytic dyskeratosis.
    Itoh Y; Asahina A; Kanbe M; Ito K; Nakagawa H
    J Dermatol; 2018 Sep; 45(9):e258-e259. PubMed ID: 29512184
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.